Ipilimumab
- Generic Name
- Ipilimumab
- Brand Names
- Yervoy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 477202-00-9
- Unique Ingredient Identifier
- 6T8C155666
- Background
Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.
Ipilimumab was granted FDA approval on 25 March 2011.
- Indication
Ipilimumab is indicated in the following cancerous conditions:
Melanoma
Renal Cell Carcinoma (RCC)
Colorectal Cancer
Hepatocellular Carcinoma
Non-Small Cell Lung Cancer (NSCLC)
Malignant Pleural Mesothelioma
Esophageal Cancer
- Treatment of adult patients with unresectable advanced or metastatic esophageal squamous cell carcinoma, as first line treatment in combination with nivolumab
- Associated Conditions
- Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Microsatellite Instability High Metastatic Colorectal Cancer (CRC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Recurrent Non-small Cell Lung Cancer, Unresectable Melanoma, Poor or intermediate risk Advanced Renal Cell Carcinoma (aRCC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- First Line Chemotherapy
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2019-05-03
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 855
- Registration Number
- NCT03937219
- Locations
- 🇺🇸
Exelixis Clinical Site #29, Boca Raton, Florida, United States
🇺🇸Exelixis Clinical Site #58A, Baltimore, Maryland, United States
🇺🇸Exelixis Clinical Site #12, Pittsburgh, Pennsylvania, United States
Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma
- Conditions
- Interventions
- First Posted Date
- 2019-04-26
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 11
- Registration Number
- NCT03929029
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Study of Immunotherapy Plus ADI-PEG 20 for the Treatment of Advanced Uveal Melanoma
- First Posted Date
- 2019-04-22
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT03922880
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer
- Conditions
- Differentiated Thyroid Gland CarcinomaFollicular Variant Thyroid Gland Papillary CarcinomaPoorly Differentiated Thyroid Gland CarcinomaRefractory Thyroid Gland CarcinomaRefractory Differentiated Thyroid Gland CarcinomaTall Cell Variant Thyroid Gland Papillary CarcinomaThyroid Gland Follicular CarcinomaThyroid Gland Oncocytic CarcinomaThyroid Gland Papillary Carcinoma
- Interventions
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 9
- Registration Number
- NCT03914300
- Locations
- 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of Kansas Cancer Center-Overland Park, Overland Park, Kansas, United States
🇺🇸University of Utah Sugarhouse Health Center, Salt Lake City, Utah, United States
A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT
- Conditions
- Interventions
- First Posted Date
- 2019-04-11
- Last Posted Date
- 2024-07-31
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 25
- Registration Number
- NCT03912064
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Brigham and Women's Hospital, Boston, Massachusetts, United States
Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer
- Conditions
- Interventions
- First Posted Date
- 2019-04-09
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- TCR2 Therapeutics
- Target Recruit Count
- 36
- Registration Number
- NCT03907852
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Duke University, Durham, North Carolina, United States
Pan Tumor Rollover Study
- Conditions
- Interventions
- Drug: NivolumabDrug: LeucovorinDrug: Nivolumab + RelatlimabDrug: RegorafinibDrug: CapecitabineDrug: PemetrexedDrug: EnzalutamideDrug: SunitinibDrug: PembrolizumabDrug: RelatlimabDrug: TemozolomideDrug: RucaparibDrug: IpilimumabDrug: DaratumumabDrug: FluorouracilDrug: CabozantinibDrug: TrametinibDrug: BevacizumabDrug: Oxaliplatin
- First Posted Date
- 2019-04-02
- Last Posted Date
- 2024-11-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 1500
- Registration Number
- NCT03899155
- Locations
- 🇧🇷
Local Institution - 0260, Belo Horizonte, Minas Gerais, Brazil
🇨🇳Harbin Medical University - Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳Local Institution - 0172, Changsha, Hunan, China
Low Dose Ipilimumab with Pembrolizumab in Treating Patients with Melanoma That Has Spread to the Brain
- Conditions
- Interventions
- First Posted Date
- 2019-03-13
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 26
- Registration Number
- NCT03873818
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
- Conditions
- Bladder Mixed AdenocarcinomaBladder Clear Cell AdenocarcinomaBladder Small Cell Neuroendocrine CarcinomaInvasive Bladder Giant Cell Urothelial CarcinomaInvasive Bladder Lymphoepithelioma-Like CarcinomaInvasive Bladder Urothelial CarcinomaMetastatic Bladder Plasmacytoid Urothelial CarcinomaMetastatic Bladder Sarcomatoid Urothelial CarcinomaMetastatic Chromophobe Renal Cell CarcinomaMetastatic Papillary Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2019-03-07
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 314
- Registration Number
- NCT03866382
- Locations
- 🇺🇸
Illinois CancerCare-Canton, Canton, Illinois, United States
🇺🇸Illinois CancerCare-Bloomington, Bloomington, Illinois, United States
🇺🇸Loyola Center for Health at Burr Ridge, Burr Ridge, Illinois, United States
Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)
- Conditions
- Interventions
- First Posted Date
- 2019-03-06
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Idera Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT03865082
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸University of Southern California/ Hoag Hospital Presbyterian, Newport Beach, California, United States
🇺🇸Banner University Medical Center Tucson Campus, Tucson, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.